Full-year organic revenue growth guidance raised to 7-9%
West Pharmaceutical reported a strong Q1 beat, driven by broad-based HVP components growth (GLP-1 and non-GLP-1) and operational improvements in Europe. Management raised full-year revenue and EPS guidance, citing continued momentum in biologics, biosimilars, Annex 1 conversion, and capacity expansion without major new capex. The SmartDose divestiture is on track for mid-year close, and the drug handling business in Dublin is ramping. Q1 revenue $845M (+21% reported, +15.3% organic), adjusted EPS $2.13 (+47%), both well above expectations.
Buzzberg readFull-year organic revenue growth guidance raised to 7-9%West Pharmaceutical reported a strong Q1 beat, driven by broad-based HVP components growth (GLP-1 and non-GLP-1) and operational improvements in Europe. Management raised full-year revenue and EPS guidance, citing continued momentum in biologics, biosimilars, Annex 1 conversion, and capacity expansion without major new capex. The SmartDose divestiture is on track for mid-year close, and the drug handling business in Dublin is ramping. Q1 revenue $845M (+21% reported, +15.3% organic), adjusted EPS $2.13 (+47%), both well above expectations.Read full analysisCollapse analysis
West Pharmaceutical reported a strong Q1 beat, driven by broad-based HVP components growth (GLP-1 and non-GLP-1) and operational improvements in Europe. Management raised full-year revenue and EPS guidance, citing continued momentum in biologics, biosimilars, Annex 1 conversion, and capacity expansion without major new capex. The SmartDose divestiture is on track for mid-year close, and the drug handling business in Dublin is ramping. Q1 revenue $845M (+21% reported, +15.3% organic), adjusted EPS $2.13 (+47%), both well above expectations.
HVP components grew 23% organically, with GLP-1 contributing ~10% of total company sales; non-GLP-1 accelerated to high teens.
Biologics (Novapure) grew 26%, driven by commercialized drugs and high win rates on new launches.
Annex 1 conversion projects up 66% YoY, expected to contribute 200bps growth in 2026 and multi-year tailwind.
Revenue$0.8449B
+5% QoQ
EPS$2.13
+4% QoQ
Gross margin35.08%
reported
Op margin20.96%
reported
What changed this quarter
01
Guidance
Full-year organic revenue growth guidance raised to 7-9%
Guidance · revenue to 3322.5
02
Demand
Annex 1 and HVP conversion expected to contribute 200 bps in 2026
Management expressed strong confidence in the business momentum, raised full-year guidance, and highlighted broad-based growth across segments, while noting prudent forecasting due to a dynamic macro environment.
03
Supply
Operational excellence initiatives ramping capacity and lowering costs
HVP components grew 23% organically, with GLP-1 contributing ~10% of total company sales; non-GLP-1 accelerated to high teens.
04
Margins
Margin expansion to continue in back half despite cost headwinds
Reported gross margin was 35.08%, reinforcing the quarter's better-than-guided profitability.
Demand & capex
Demand
Bookings & conversion
Annex 1 and HVP conversion expected to contribute 200 bps in 2026. Management expressed strong confidence in the business momentum, raised full-year guidance, and highlighted broad-based growth across segments, while noting prudent forecasting due to a dynamic macro environment.
Capex
Investment and capacity
Management emphasized operational excellence and leveraging existing capacity to meet demand, while keeping capital expenditure expectations at $250-275 million for the year, even with increased revenue guidance. They highlighted initial cost investments in ramping up production and onboarding employees, which are expected to generate ongoing benefits.
Tone · Upbeat
Management expressed strong confidence in the business momentum, raised full-year guidance, and highlighted broad-based growth across segments, while noting prudent forecasting due to a dynamic macro environment.
Supply-chain alpha
A1
Non-GLP-1 HVP components growth accelerated to high teens in Q1, and demand is outpacing supply as seen in Q4; operational redeployment and site qualifications are unlocking incremental capacity without new capex.
“In Q4, we talked about demand outstripping supply. We're continuing to ramp and feel good about the team's ability to continue to meet that demand for the rest of the year.”
Annex 1 conversion projects increased 66% year-over-year, and the tailwind is expanding beyond Europe into the US and Asia as regulators heighten sterility standards.
“Annex 1 related projects increased sequentially and is up 66% as compared to this time last year.”